BGI
BGI Genomics Program Seeks to Validate Signatera Test for Colorectal Cancer Patients in China
Premium
The molecular residual disease test from Natera was first made available to biopharmaceutical customers and clinicians across China in June.
Although demand for the firm's COVID-19 testing declined in H1, other diagnostic areas and its international business have grown.
BGI Genomics H1 Revenues Fall 11 Percent on COVID-19 Testing Decline
The firm's other businesses saw steady growth, with cancer prevention revenues up 94 percent and infection prevention and control revenues more than tripling.
BGI Americas, Advaite Form SARS-CoV-2 Testing Partnership
Through the deal, BGI Americas will offer its PCR-based SARS-CoV-2 detection kit with Advaite's COVID-19 immunoassay, both of which have FDA authorization.
BGI Genomics Nabs CE Mark for Colorectal Cancer Screening Test
The real-time PCR test can detect abnormal methylation of SDC2, ADHFE1, and PPP2R5C genes in stool DNA, which are markers for colorectal cancer cells.